文献速递神经肿瘤

贝伐珠单抗-IRDye800CW作为荧光引导脑膜瘤手术示踪剂的可行性

Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery.
PubMed 文献 · J Neurosurg · 2022-10-28

本研究在CH-157MN异种移植小鼠模型中评估贝伐珠单抗-IRDye800CW靶向血管内皮生长因子α用于脑膜瘤荧光引导手术的可行性。结果显示肿瘤在注射后24、48、72小时均发出荧光且背景荧光随时间下降,离体分析示肿瘤组织荧光最高,荧光定位于细胞质并与血管内皮生长因子α表达模式相关,荧光引导下可检出肿瘤主体及小残留灶;贝伐珠单抗-IRDye800CW特异性结合所有受试人脑膜瘤标本,作者认为下一步将在人体试验中评估其优化脑膜瘤切除的可行性。

要点

  • 在CH-157MN异种移植小鼠模型中,贝伐珠单抗-IRDye800CW注射后24、48、72小时肿瘤均发出荧光,背景荧光随时间下降。
  • 离体生物分布显示肿瘤组织荧光最高,脑、颅骨和肌肉组织荧光很低。
  • 荧光位于细胞质并与血管内皮生长因子α表达模式相关,荧光引导下检出肿瘤主体及小残留灶。

核心结论

  • 贝伐珠单抗-IRDye800CW在脑膜瘤异种移植小鼠模型中显示脑膜瘤特异性,表现为血管内皮生长因子α介导的高摄取。
  • 荧光引导下可检出小肿瘤病灶,作者认为下一步将在人体试验中评估已可获得的临床级贝伐珠单抗-IRDye800CW优化脑膜瘤切除的可行性。

研究设计与样本

  • 在5只体积为500 mm3的CH-157MN异种移植小鼠中静脉给予贝伐珠单抗-IRDye800CW,于注射后24、48、72小时用FMT2500荧光成像系统进行在体成像。
  • 注射后72小时用Pearl荧光成像仪进行离体生物分布测定。
  • 2只动物在死后模拟临床场景,在白光和荧光引导下进行异种移植瘤切除。
  • 新鲜和冷冻人脑膜瘤标本离体与贝伐珠单抗-IRDye800CW孵育,用抗血管内皮生长因子α染色后显微镜检查。

主要发现

  • 在体成像中,肿瘤在示踪剂给药后所有时间点均发出荧光,背景荧光随时间下降。
  • 离体生物分布分析显示切除肿瘤组织荧光最高,脑、颅骨和肌肉组织荧光很低。
  • 显微镜下荧光位于细胞质,并与血管内皮生长因子α表达模式相关。
  • 死后手术中,荧光引导下检出肿瘤主体和一个小肿瘤残留灶。
  • 贝伐珠单抗-IRDye800CW特异性结合所有受试人脑膜瘤标本,肿瘤主体荧光信号高,周围健康硬脑膜荧光信号低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Meningiomas are frequently occurring, often benign intracranial tumors. Molecular fluorescence can be used to intraoperatively identify residual meningioma tissue and optimize safe resection; however, currently no clinically approved agent is available for this specific tumor type. In meningiomas, vascular endothelial growth factor α (VEGFα) is upregulated, and this biomarker could be targeted with bevacizumab-IRDye800CW, a fluorescent agent that is already clinically applied for the resection of other tumors and neoplasms. Here, the authors investigated the feasibility of using bevacizumab-IRDye800CW to target VEGFα in a CH-157MN xenografted mouse model. METHODS: Five mice with CH-157MN xenografts with volumes of 500 mm3 were administered intravenous bevacizumab-IRDye800CW. Mice were imaged in vivo at 24 hours, 48 hours, and 72 hours after injection with the FMT2500 fluorescence imaging system. Biodistribution was determined ex vivo using the Pearl fluorescent imager at 72 hours after injection. To mimic a clinical scenario, 2 animals underwent postmortem xenograft resection using both white-light and fluorescence guidance. Lastly, fresh and frozen human meningioma specimens were incubated ex vivo with bevacizumab-IRDye800CW, stained with anti-VEGFα, and microscopically examined. RESULTS: In vivo, tumors fluoresced at all time points after tracer administration and background fluorescence decreased with time. Ex vivo analyses of tracer biodistribution showed the highest fluorescence in resected tumor tissue. Brain, skull, and muscle tissue showed very low fluorescence. Microscopically, fluorescence was observed in the cytoplasm and was correlated with VEGFα expression patterns. During postmortem surgery, both the tumor bulk and a small tumor remnant were detected. Bevacizumab-IRDye800CW bound specifically to all tested human meningioma samples, as indicated by a high fluorescent signal in the tumor bulk compared with the surrounding healthy dura mater. CONCLUSIONS: Bevacizumab-IRDye800CW showed meningioma specificity, as illustrated by high VEGFα-mediated uptake in the meningioma xenograft mouse model. Small tumor lesions were detected using fluorescence guidance. Thus, the next step will be to assess the feasibility of using already available clinical grade bevacizumab-IRDye800CW to optimize meningioma resection in a human trial.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Dijkstra BM, Nonnekens J, Nagengast W, et al. Feasibility of bevacizumab-IRDye800CW as a tracer for fluorescence-guided meningioma surgery. J Neurosurg. 2022. PMID: 36308486. doi:10.3171/2022.9.JNS221036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。